{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:26:02Z","timestamp":1791559562438,"version":"4.3.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>A 74-year-old male patient with renal cell carcinoma developed disease progression in the left adrenal gland and lungs 12.8\u00a0years after surgery. He presented with symptoms of cholecystitis 4\u00a0weeks after starting pazopanib and 8\u00a0weeks after starting axitinib. The symptoms were relieved after treatment with drug discontinuation, anti-infective therapy and symptomatic supportive care. The Naranjo Adverse Drug Reaction Probability Scale scores showed 4 points for pazopanib and 6 points for axitinib, indicaing a probable association of the event with the above two drugs. Meanwhile, a literature review was conducted by retrieving studies on tyrosine kinase inhibitor-induced cholecystitis from the PubMed database from 2005 to 2025, followed by systematic collation and summary. The study suggests that anti-angiogenic tyrosine kinase inhibitors may induce rare episodes of cholecystitis in specific patient populations. Clinicians should maintain adequate vigilance, conduct close clinical monitoring, and adjust therapeutic regimens in a timely manner to ensure patient safety and optimize prognosis.<\/jats:p>","DOI":"10.3389\/fphar.2026.1928976","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:46:17Z","timestamp":1788932777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of recurrent acute acalculous cholecystitis in a patient with renal cell carcinoma treated with pazopanib and axitinib: case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaolu","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueru","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4251\/wjgo.v4.i5.115","article-title":"A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma","volume":"4","author":"Aihara","year":"2012","journal-title":"World J. Gastrointest. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European association of urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.6004\/jnccn.2009.0044","article-title":"Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance","volume":"7","author":"Chen","year":"2009","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4166\/kjg.2020.75.2.103","article-title":"Acute acalculous cholecystitis associated with sunitinib treatment for renal cell carcinoma","volume":"75","author":"Choi","year":"2020","journal-title":"Korean J. Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4081\/cp.2014.635","article-title":"Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib","volume":"4","author":"da Fonseca","year":"2014","journal-title":"Clin. Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1592\/phco.27.5.775","article-title":"Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib","volume":"27","author":"de Lima Lopes","year":"2007","journal-title":"Pharmacotherapy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract. and Res. Clin. Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11523-017-0511-8","article-title":"Pazopanib: a review in advanced renal cell carcinoma","volume":"12","author":"Frampton","year":"2017","journal-title":"Target. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.14740\/jocmr1850w","article-title":"Acute acalculous cholecystitis in patients with clear cell renal cell carcinoma treated with sunitinib: report of two cases","volume":"6","author":"Furubayashi","year":"2014","journal-title":"J. Clin. Med. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.2022.2350","article-title":"Acute cholecystitis: a review","volume":"327","author":"Gallaher","year":"2022","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1053\/j.gastro.2005.12.034","article-title":"Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism","volume":"130","author":"Gaudio","year":"2006","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3816\/CGC.2009.n.011","article-title":"Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib","volume":"7","author":"Gomez-Abuin","year":"2009","journal-title":"Clin. Genitourin. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2169\/internalmedicine.3806-19","article-title":"Repeated perforation of the gallbladder in a patient with hepatocellular carcinoma receiving lenvatinib","volume":"59","author":"Honda","year":"2020","journal-title":"Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.urology.2016.12.035","article-title":"Axitinib-induced pneumatosis intestinalis and acute acalculous cholecystitis in a patient with renal cell carcinoma","volume":"101","author":"Kameda","year":"2017","journal-title":"Urology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s40265-015-0483-x","article-title":"Axitinib: a review in advanced renal cell carcinoma","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3349\/ymj.2023.0587","article-title":"Incidence and pattern of recurrence after surgical resection in organ-confined renal cell carcinoma","volume":"65","author":"Kim","year":"2024","journal-title":"Yonsei Med. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1585862","DOI":"10.3389\/fphar.2025.1585862","article-title":"Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1752-1947-6-69","article-title":"Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report","volume":"6","author":"Nakano","year":"2012","journal-title":"J. Med. Case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"201529","DOI":"10.5402\/2011\/201529","article-title":"Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib","volume":"2011","author":"Sanda","year":"2011","journal-title":"ISRN Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1124\/jpet.121.000828","article-title":"Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors","volume":"380","author":"Saran","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/diagnostics14182105","article-title":"Imaging in renal cell carcinoma detection","volume":"14","author":"Woon","year":"2024","journal-title":"Diagn. (Basel)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1928976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:46:18Z","timestamp":1788932778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1928976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1928976"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1928976","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1928976"}}